Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | USP7 | Q93009 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17437460 | 0.92 | RPS6KA5 (0.34) | TLR8USP7ADORA2A | |
| SCHEMBL17437378 | 0.89 | TLR8 (0.35) | TLR8POLBHSD17B10 | |
| SCHEMBL17437512 | 0.86 | CYP11B2 (0.34) | TLR8ADORA2A | |
| SCHEMBL17437352 | 0.84 | DYRK1A (0.36) | — | |
| SCHEMBL16054029 | 0.82 | ADORA2A (0.32) | POLBADORA2AADORA2BADORA1 | |
| SCHEMBL16053847 | 0.81 | RPS6KA5 (0.36) | TLR8ADORA2AMAPK14ALDH1A1HSD17B10 | |
| SCHEMBL17437549 | 0.81 | DPP4 (0.36) | — | |
| SCHEMBL17437584 | 0.81 | CYP3A4 (0.38) | TLR8ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL17437368 | 0.81 | RPS6KA5 (0.39) | — | |
| SCHEMBL17437525 | 0.81 | ADORA2A (0.32) | POLBADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050963-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-02-23 | — | — | US | disclosed |
| US-9512120-B2 | Microbicidally active imidazopyridine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-06 | — | — | US | disclosed |
| US-20160016949-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050963-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | IDO1, IDO2, FOXM1 | TLR8 382/4885POLB 1804/4885TP53 1980/4885 |
| US-20160016949-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | IDO1, IDO2, FOXM1 | TLR8 382/4885POLB 1804/4885TP53 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.